← Back to Search

Monoclonal Antibodies

XmAb27564 for Safety

Phase 1
Waitlist Available
Research Sponsored by Xencor, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests a new protein treatment, XmAb27564, in healthy men and women to see if it is safe. The treatment aims to help with autoimmune diseases by changing how the immune system works.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or FExperimental Treatment1 Intervention
Group II: Single Ascending Dose - Placebo Subcutaneous injection of placeboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XmAb27564
2021
Completed Phase 1
~50

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Xencor, Inc.Lead Sponsor
29 Previous Clinical Trials
2,400 Total Patients Enrolled
ICON Clinical ResearchIndustry Sponsor
50 Previous Clinical Trials
15,216 Total Patients Enrolled
David Liebowitz, MDStudy DirectorVice President, Clinical Development, Xencor
2 Previous Clinical Trials
468 Total Patients Enrolled
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top